We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jul 2020 - 10 Jul 2020
Virtual Venue
27 Jul 2020 - 30 Jul 2020

Proenkephalin Assesses True Glomerular Filtration Rate Accurately

By LabMedica International staff writers
Posted on 02 Mar 2020
Print article
Image: The penKid assay allows the measurement of actual kidney function with a simple blood draw. Being non-inferior to the gold standard, rising and decreasing penKid values reveal worsening and improving of kidney function independent from inflammation or any other comorbidity, allowing the inclusion of all critical ill patients (Photo courtesy of SphingoTec GmbH).
Image: The penKid assay allows the measurement of actual kidney function with a simple blood draw. Being non-inferior to the gold standard, rising and decreasing penKid values reveal worsening and improving of kidney function independent from inflammation or any other comorbidity, allowing the inclusion of all critical ill patients (Photo courtesy of SphingoTec GmbH).
The assessment of renal function in clinical practice remains challenging. Using creatinine to assess the glomerular filtration rate (GFR) is notoriously inaccurate, and determination of the true GFR, such as using inulin or iohexol, is laborious and not feasible in daily practice.

Proenkephalin (PENK) is a novel candidate biomarker for kidney function that is filtrated in the glomerulus, shown to represent steady-state GFR in patients with different severities of renal insufficiency and is reliably predictive for acute kidney injury in patients with severe burns. Although AKI is a major complication in critically ill patients, current diagnostic standard methods do not properly and timely diagnose impaired renal function.

Scientists at the Radboud University Medical Center (Nijmegen, the Netherlands) conducted a pilot study in non-steady-state critically ill patients, and compared plasma PENK concentrations with creatinine-based GFR assessments and validated both against the ‘true GFR’ measured using a gold standard method: iohexol plasma clearance.

The investigators included 23 critically ill patients with septic shock. Kidney function was determined using the Modification of Diet in Renal Disease formula (eGFRMDRD), Endogenous Creatinine Clearance (GFRECC), and iohexol plasma clearance (GFRiohexol) during a 6-hour window. Plasma PENK concentrations were measured using the penKid immunoassay (SphingoTec GmbH, Hennigsdorf Germany).

The scientists reported that the eGFRMDRD and GFRECC correlated with the GFRiohexol (R2 = 0.82, p < 0.0001 and R2 = 0.82, p < 0.0001 respectively), however bias and variability were considerable: the eGFRMDRD overestimated the true GFR with 31 ± 35% (95% limits of agreement: -37 to 100%) and the GFRECC with 37 ± 49% (95% limits of agreement: -59 to 133%). Plasma PENK concentrations showed a very strong inverse correlation with the GFRiohexol which tended to be better compared to the correlation of eGFRMDRD and GFRECC with the GFRiohexol.

Andreas Bergmann, PhD, CEO of Sphingotec, commented, "penKid is an early renal function biomarker that is not biased by co-morbidities while reflecting true GFR. penKid has been tested for the first time to identify ICU patients with severe burns that need rapid and aggressive intervention to prevent mortality caused by AKI.”

The authors concluded that in non-steady state critically ill sepsis patients, GFR appears to be more accurately reflected by plasma PENK concentrations compared to conventional creatinine-based methods. Therefore, PENK holds promise as an accurate and feasible biomarker to determine kidney function during non-steady-state conditions in the critically ill. The study was published ahead of print on January 21, 2020 in the journal SHOCK.

Related Links:
Radboud University Medical Center
SphingoTec GmbH



Print article

Channels

Molecular Diagnostics

view channel
Image: The Chemagic 360 extracts DNA and uses transiently magnetized rods to attract the beads after binding to the nucleic acids (Photo courtesy of PerkinElmer).

Blood Group Locus Contributes to COVID-19 Severity Risk

There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19).... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.